In order to further observe the long-term safety and effectiveness of real-world polyethylene glycol-recombinant human growth hormone(PEG-rhGH) treatment of GHD, idiopathic short stature, and SGA in children, explore and analyze the factors affecting the efficacy of PEG-rhGH and the height prediction model after treatment, etc., collect and analyze more scientifically and rationally, and understand the situation of real-world PEG-GH treatment. A database registration study was developed.
A database registration study was developed to retrospectively analyze the efficacy and safety of polyethylene glycol recombinant human growth hormone injection in the treatment of slow growth in children caused by endogenous growth hormone deficiency, idiopathic short stature, Turner syndrome, etc., and to further prospectively follow up and monitor. In order to participate in the global real-world use of long-acting growth hormone, all data from this study were uploaded to the Global Registry of New Therapies for Rare Endocrine Diseases and Bone Disorders (GloBE-Reg) platform.
Study Type
OBSERVATIONAL
Enrollment
2,600
0.1-0.3mg/kg.w
Department of Endocrinology, Genetics, Metabolism
Beijing, Beijing Municipality, China
RECRUITINGthe change in height standard deviation score
final adult height standard deviation score- height standard deviation score before treatment
Time frame: 3-10years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.